Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide in Combination With Radiochemotherapy or Radioimmunotherapy in SCLC
NCT03467360Phase 1Recruiting
- Sponsor
- Centre Antoine Lacassagne
- Start
- Aug 2019
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of acetazolamide in small cell lung cancer (SCLC) (2 arms), sponsored by Centre Antoine Lacassagne. Primary endpoint: Maximum Tolerated Dose at 8 months. Started Aug 2019; status: recruiting.
02
Drugs
acetazolamide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03467360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467360.